肿瘤相关内皮祖细胞生物学性状分析、比较
Analysis and Comparison of Biological Characteristics of Tumor Related Endothelial Progenitor Cells
DOI: 10.12677/ACM.2018.82042, PDF,    科研立项经费支持
作者: 闫 堃*, 徐 心, 王志亮, 李 杰, 纪宗正, 黎一鸣, 吴 涛, 曹 罡, 段艳霞:西安交通大学医学院第二附属医院普通外科,陕西 西安;程 玮:西安市儿童医院呼吸内科,陕西 西安
关键词: 血管生成内皮祖细胞生物学性状肝癌脾脏Angiogenesis Endothelial Progenitor Cells Biological Characteristics Liver Cancer Spleen
摘要: 目的:以正常人为对照探讨内皮祖细胞在肝癌患者中组织学分布的差异性、分析其表面标志物表达情况、细胞形态变化、增殖和管形成能力改变。方法:密度梯度离心、免疫磁珠贯序分离获取单个核细胞,用条件分化培养基进行分化刺激培养,直到分化成熟为内皮细胞。流式检测其生物标志物变化情况。分化潜能,倍增能力,功能状况。结果:单个核细胞经条件诱导培养可定向分化为内皮祖细胞,表现出部分血管内皮的功能特征。肝癌患者骨髓、外周血与正常人无差异,脾内内皮祖细胞系分化明显增强。结论:来源于骨髓单个核细胞分布于多个组织中,可定向分化为内皮祖细胞,进而成熟为内皮细胞,此过程干/祖细胞的生物学特征逐渐降低直至消失。肝癌患者脾脏为此过程提供了最佳的分化诱导内环境。
Abstract: Objective: Our study aims to assess the difference of endothelial progenitor cells (EPC) between normal controls and liver cancer patients, and to explore the sources, distribution, tube formation ability and biomarker of EPC. Methods: The mononuclear cells were separated by density gradient centrifugation bind with immune magnetic beads. They could develop into the endothelial cells with conditions medium stimulate regeneration. Flow cytometer technology detected the surface antigen changes of all process. Results: The mononuclear cells could induce to develop into the EPC. There is no difference between the liver cancer patients and normal controls in bone marrow and peripheral blood. But the endothelial progenitor cells from the spleen are obviously increased in the liver cancer patients. Conclusion: The mononuclear cells, which derived from bone marrow and distributed in all organization, could develop into EPC and the endothelial cells. The biological characters of progenitor cells reduced gradually during this process. The microenvironment of spleen in liver cancer patients are the favorable to the differentiation of mononuclear cells.
文章引用:闫堃, 程玮, 徐心, 王志亮, 李杰, 纪宗正, 黎一鸣, 吴涛, 曹罡, 段艳霞. 肿瘤相关内皮祖细胞生物学性状分析、比较[J]. 临床医学进展, 2018, 8(2): 247-252. https://doi.org/10.12677/ACM.2018.82042

参考文献

[1] Bilusic, M. and Wong, Y.N. (2014) Anti-Angiogenesis in Prostate Cancer: Knocked Down but Not Out. Asian Journal of Andrology, 16, 372-377.
[Google Scholar] [CrossRef
[2] Bielenberg, D.R. and Zetter, B.R. (2015) The Contribution of Angiogenesis to the Process of Metastasis. Cancer Journal, 21, 267-273.
[Google Scholar] [CrossRef
[3] Bertz, S., et al. (2014) Increased Angiogenesis and FGFR Protein Ex-pression Indicate a Favourable Prognosis in Bladder Cancer. Virchows Archv, 465, 687-695.
[Google Scholar] [CrossRef] [PubMed]
[4] Berretta, M., et al. (2016) Angiogenesis Inhibitors for the Treatment of Hepa-tocellular Carcinoma. Frontiers in Pharmacology, 7, 428.
[Google Scholar] [CrossRef] [PubMed]
[5] Yu, P., et al. (2016) Progesterone Modulates Endothelial Progenitor Cell (EPC) Viability through the CXCL12/ CXCR4/PI3K/Akt Signalling Pathway. Cell Proliferation, 49, 48-57.
[Google Scholar] [CrossRef] [PubMed]
[6] Baharara, J., et al. (2014) Anti-Angiogenesis Effect of Biogenic Silver Nanoparticles Synthesized Using Saliva officinalis on Chick Chorioalantoic Membrane (CAM). Molecules, 19, 13498-13508.
[Google Scholar] [CrossRef] [PubMed]
[7] Salajegheh, A. (2016) Angiogenesis in Health, Diseases and Malignancy. Springer International Publishing Switzerland. Anticancer Research, 36, 3226.
https://www.ncbi.nlm.nih.gov/pubmed/27272869
[8] Ziebart, T., et al. (2016) Significance of Endothelial Progenitor Cells (EPC) for Tumorigenesis of Head and Neck Squamous Cell Carcinoma (HNSCC): Possible Marker of Tumor Progression and Neo-vascularization? Clinical Oral Investigations, 20, 2293-2300.
[Google Scholar] [CrossRef] [PubMed]
[9] Falay, M. and Aktas, S. (2016) Endothelial Progenitor Cells (EPC) Count by Multicolor Flow Cytometry in Healthy Individuals and Diabetes Mellitus (DM) Patients. Clinical Laboratory, 62, 2161-2166.
[Google Scholar] [CrossRef
[10] Paynter, R., et al. (2017) Commentary on EPC Methods: An Exploration of the Use of Text-Mining Software in Systematic Reviews. Journal of Clinical Epidemiology, 84, 33-36.
[Google Scholar] [CrossRef] [PubMed]
[11] Altabas, V., Altabas, K. and Kirigin, L. (2016) Endothelial Progenitor Cells (EPCs) in Ageing and Age-Related Diseases: How Currently Available Treatment Modalities Affect EPC Biology, Atherosclerosis, and Cardiovascular Outcomes. Mechanisms of Ageing and Development, 159, 49-62.
[Google Scholar] [CrossRef] [PubMed]
[12] Wojakowski, W., et al. (2013) Circulating Endothelial Progenitor Cells Are Inversely Correlated with In-Stent Restenosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes Treated with EPC-Capture Stents (JACK-EPC Trial). Minerva Cardioangiologica, 61, 301-311.
[13] Povsic, T.J., et al. (2013) EPC Mobilization after Erythropoietin Treatment in Acute ST-Elevation Myocardial Infarction: the REVEAL EPC Substudy. Journal of Thrombosis and Thrombolysis, 36, 375-383.
[Google Scholar] [CrossRef] [PubMed]
[14] Yongxiang, W., et al. (2002) Effects of Splenomegaly and Splenic Macrophage Activity in Hypersplenism Due to Cirrhosis. The American Journal of Medicine, 113, 428-431.
[Google Scholar] [CrossRef
[15] Folkman, J., et al. (1971) Isolation of a Tumor Factor Responsible for Angiogenesis. Journal of Experimental Medicine, 133, 275-288.
[Google Scholar] [CrossRef] [PubMed]
[16] Robinson, K.A., et al. (2016) Twelve Recommendations for Integrating Existing Systematic Reviews into New Reviews: EPC Guidance. Journal of Clinical Epidemiology, 70, 38-44.
[Google Scholar] [CrossRef] [PubMed]